First Department of Internal Medicine.
Leuk Lymphoma. 2013 Oct;54(10):2144-8. doi: 10.3109/10428194.2013.775434. Epub 2013 Mar 27.
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients with Hodgkin lymphoma (HL). We thus retrospectively analyzed 14 patients with primary refractory or relapsed HL who were treated with brentuximab vedotin as single agent in a named patient program, who had not received prior high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) due to refractory disease (n = 9), comorbidity (n = 4) and unknown reasons (n = 1). Brentuximab vedotin resulted in an overall response rate of 71% (10/14) with five complete responses (CRs). Five of those patients with refractory disease and four patients with relevant comorbidity responded. Consolidating ASCT (n = 4) or allogeneic SCT (n = 1) was performed in five patients. Median progression-free survival (PFS) was 9 months and the median overall survival (OS) was not reached. These data indicate the therapeutic efficacy of brentuximab vedotin in chemotherapy-refractory transplant-naive patients with HL.
仅有有限的数据可用于评估本妥昔单抗维布妥昔单抗（SGN-35）在初治复发或难治性霍奇金淋巴瘤（HL）患者中的作用。因此，我们回顾性分析了 14 例在一项上市后项目中接受本妥昔单抗维布妥昔单抗单药治疗的原发性难治性或复发 HL 患者，这些患者由于疾病难治（n = 9）、合并症（n = 4）和未知原因（n = 1）而未接受先前的高剂量化疗（HDCT）和自体干细胞移植（ASCT）。本妥昔单抗维布妥昔单抗治疗的总体缓解率为 71%（10/14），其中 5 例为完全缓解（CR）。疾病难治的 5 例患者和合并症相关的 4 例患者有缓解。5 例患者接受了巩固性 ASCT（n = 4）或异基因 SCT（n = 1）。中位无进展生存期（PFS）为 9 个月，中位总生存期（OS）尚未达到。这些数据表明本妥昔单抗维布妥昔单抗在化疗难治性初治 HL 患者中的治疗疗效。
